Premature Atherosclerotic Cardiovascular Disease in Systemic Lupus Erythematosus: Understanding Management Strategies

Journal of Cardiovascular Nursing

Volumn 28, Issue 1, 2013, Pages 48-53

  Turano, Lillian ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

atherosclerosis; cardiovascular system; lupus erythematosus; risk management; systemic

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; HUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84871726056     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e3182363e3b     Document Type: Article

References (26)

1. Bhornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-1995. J Rheumatol. 2004;31(4):713-719.
2. Schattner A, Liang MH. The cardiovascular burden of lupus: a complex challenge. Arch Intern Med. 2003;163(13): 1507-1510.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account foraccelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-2337.
4. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407-2415.
5. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399-2406.
6. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates ofmyocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145(5): 408-415.
7. Huether S, McCance K. Understanding Pathophysiology. 4th ed. St Louis, MO: Mosby Elsevier; 2008.
8. Lockshin MD. An indepth topic review of systemic lupus erythematosus. Hospital for Special Surgery. Updated 2004. from http://www.hss.edu/ professional-conditions-13437 .asp#When-to-Refer. Accessed November 16, 2010.
9. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
10. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev. 2004;12(5):267-275.
11. Elliott JR, Manzi S. Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2009;23(4):481-494.
12. Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56(10): 3412-3419.
13. Kaplan MJ. Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? Transl Res. 2009;154(2):61-69.
14. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson- Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum. 2002;46(11):2957-2963.
15. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2006;66(2): 208-214.
16. Rho YH, Chung CP, Oeser A, et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008; 35(9):1789-1794.
17. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54(8): 2541-2549.
18. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103(10):3677-3683.
19. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial cell progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999- 1007.
20. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007;110(8): 2907-2915.
21. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosusV proposed guidelines for risk factor management. Rheumatology. 2004;43(1):7-12.
22. Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2005;2(8):423-430.
23. Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumatol. 2010;5(1):75-100.
24. National Kidney Foundation. K/DOQI Clinical practice guidelines on hypertension and angiotensin receptor blockers in chronic kidney disease. National Kidney Foundation Website. http://www.kidney.org/professionals/kdoqi/ guidelines-bp/guide-11.htm. Accessed August 12, 2011.
25. Chogle AR, Chakravarty A. Cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis: emerging concepts, early diagnosis and management. J Assoc Physicians India. 2007;55:32-40.
26. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999;26:2137-2143.